| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
L-Valine-d8 shares the same metabolic role as its non-deuterated form, L-valine. L-Valine is an essential branched-chain amino acid (BCAA) that is a precursor for the synthesis of proteins and is involved in energy metabolism, muscle synthesis, and neurotransmitter regulation. The labeled compound is used as an internal standard for the quantification of valine in biological samples.
|
|---|---|
| ln Vitro |
The deuterated compound itself does not possess intrinsic pharmacological activity in vitro; its biological activity is identical to that of L-valine. L-Valine is an essential amino acid that is incorporated into proteins and serves as a precursor for other metabolites. The labeled compound is used as an internal standard for quantifying valine in biological samples, not for evaluating its own biological activity.
|
| ln Vivo |
L-Valine-d8 is not used as a therapeutic agent; its non-deuterated form, L-valine, is an essential amino acid obtained from the diet. In vivo, valine is incorporated into proteins and metabolized in muscle tissue. The labeled compound is used in pharmacokinetic and metabolic studies to accurately measure valine levels in plasma, urine, and tissue samples.
|
| Enzyme Assay |
In vitro assays for L-valine-d8 focus on its use as an analytical standard. A standard protocol involves preparing a solution of the compound in an appropriate solvent (e.g., water or methanol) and using it as an internal standard for LC-MS or GC-MS analysis of valine in biological samples. The compound is added to samples before extraction and derivatization procedures. Quantification is performed by monitoring specific mass transitions for the labeled and unlabeled compounds.
|
| Cell Assay |
In vitro cell culture experiments are not performed with L-valine-d8. When studying the effects of valine in cellular systems, the non-labeled compound is used. Cells are treated with valine, and protein synthesis or metabolic pathways are measured. The labeled compound is used as an internal standard for LC-MS analysis.
|
| Animal Protocol |
In vivo animal studies are not conducted with L-valine-d8. When used in pharmacokinetic studies, the labeled compound serves as an internal standard for the quantification of valine in animal plasma or tissue samples.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of L-valine-d8 itself are not characterized, as it is not a drug substance. L-Valine is an essential amino acid that is absorbed from the diet and metabolized primarily in muscle tissue. The labeled compound is used as an internal standard for pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
L-Valine-d8 is not a therapeutic agent and has not been evaluated for toxicity in humans. L-Valine is an essential amino acid that is generally recognized as safe at recommended dietary levels. The labeled compound is for research use only and should be handled with standard laboratory precautions.
|
| References |
|
| Additional Infomation |
L-valine-d8 is a deuterated compound of L-valine.
L-Valine-d8 is a stable isotope-labeled internal standard used for the quantification of valine in biological samples. It is also known as L-valine-2,3,4,4,4,5,5,5-d8. The compound is used in analytical method development, quality control, and metabolic studies. |
| Molecular Formula |
C5H3D8NO2
|
|---|---|
| Molecular Weight |
125.20
|
| Exact Mass |
125.129
|
| CAS # |
35045-72-8
|
| PubChem CID |
12169458
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
213.6±23.0 °C at 760 mmHg
|
| Melting Point |
295-300 ℃ (subl. )(lit.)
|
| Flash Point |
83.0±22.6 °C
|
| Vapour Pressure |
0.1±0.9 mmHg at 25°C
|
| Index of Refraction |
1.461
|
| LogP |
0.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
8
|
| Complexity |
90.4
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[2H][C@@](C(=O)O)(C([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])N
|
| InChi Key |
KZSNJWFQEVHDMF-AYWPRJOCSA-N
|
| InChi Code |
InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/t4-/m0/s1/i1D3,2D3,3D,4D
|
| Chemical Name |
(2S)-2-amino-2,3,4,4,4-pentadeuterio-3-(trideuteriomethyl)butanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ≥ 41.67 mg/mL (332.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.9872 mL | 39.9361 mL | 79.8722 mL | |
| 5 mM | 1.5974 mL | 7.9872 mL | 15.9744 mL | |
| 10 mM | 0.7987 mL | 3.9936 mL | 7.9872 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
